UP 127% in a year, why is the Pro Medicus share price rocketing higher again today?

ASX investors are sending Pro Medicus shares flying higher on Thursday. But why?

The Pro Medicus Ltd (ASX: PME) share price is racing higher today.

Shares in the S&P/ASX 200 Index (ASX: XJO) health imaging company closed yesterday trading for $285.20. In morning trade on Thursday, shares are changing hands for $308.87 apiece, up 8.3%.

This sees the Pro Medicus share price up a whopping 126.5% over 12 months.

For some context, the ASX 200 is down 0.1% today and up 11.0% in a year.

Today's outperformance follows on news of two new major contract wins for the company's Visage Imaging Platform.

Both new contracts were signed by Pro Medicus' wholly owned United States subsidiary, Visage Imaging.

Three scientists wearing white coats and blue gloves dance together in a lab.

Image source: Getty Images

Pro Medicus share price leaps on contract wins

The first announcement that looks to be supporting the Pro Medicus share price today is the renewal of a five-year contract and a new Visage 7 Open Archive contract the company inked with Franciscan Missionaries of Our Lady Health System, based in the US state of Louisiana.

The company said the contract with FMOLHS has a minimum value of $20 million. Both the renewal and Visage 7 Open Archive contracts are transaction-based.

"This deal confirms our belief that there is a material opportunity for us to sell Visage 7 Open Archive to our existing base of 'viewer only' clients," Pro Medicus CEO Sam Hupert said.

"Over time, we believe those customers with on premise implementations will join FMOLHS and a growing number of existing clients in transitioning to cloud, a trend we see continuing," he added.

What other new contract did the ASX 200 healthcare stock announce?

The Pro Medicus share price is also catching tailwinds from a second new contract win.

Management reported that the company has signed a $170 million, 10-year contract with UCHealth, based in the US state of Colorado.

According to the release, UCHealth spans a network of 14 hospitals, with affiliate hospitals, clinic locations, and health care providers throughout Colorado, Wyoming, and western Nebraska.

The new contract will see the ASX 200 healthcare stock's cloud-based Visage 7 Enterprise Imaging Platform implemented throughout UCHealth, which the company noted will provide a single, unified enterprise imaging platform.

Commenting on the contract with UCHealth that's helping boost the Pro Medicus share price today, Hupert said:

They join an ever-growing list of Visage 7 clients to opt for our fully cloud-based solution, which, as a result of our CloudPACS strategy, is becoming the standard in the North American healthcare IT market.

Looking ahead, he added:

Our pipeline remains strong and spans all market segments. There is growing interest in our 'full stack' solution comprising all three core Visage products, viewer, workflow, and archive with the added option of 'other ologies' such as cardiology.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

ResMed vs Fisher & Paykel Healthcare: Which is better value?

How do ResMed and Fisher & Paykel compare on value, income, and share price momentum? Here’s my verdict on which…

Read more »

Happy doctor using her laptop.
Healthcare Shares

CSL unveils exclusive Alentis deal to advance rare disease treatments

CSL unveils a major partnership for rare disease drug development, enhancing its global nephrology strategy.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

Could this ASX biotech really jump more than 80% in value?

This company's new technology has one broker impressed.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

CSL vs Pro Medicus: Which ASX healthcare share is better?

Both CSL and Pro Medicus have faced recent challenges but have enviable long-term track records. Here's which one I'd buy…

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

This ASX biotech could rise almost 50%, Morgans says

Turning science into contracts could unlock value for this company.

Read more »

Doctor with stethoscope using a tablet in a hospital.
Healthcare Shares

Telix Pharmaceuticals wins FDA Fast Track for BiPASS prostate cancer imaging

Telix Pharmaceuticals shares are in the spotlight after the FDA granted Fast Track for its BiPASS pre-biopsy prostate cancer imaging…

Read more »

Three scientists looking at a laptop in a lab.
Healthcare Shares

What would it take for CSL shares to return to $250?

The shares have already recovered strongly, so I wanted to see whether $250 is realistic.

Read more »

Doctor with stethoscope typing on her computer.
Healthcare Shares

Is the ResMed share price a cheap buy?

I look at what the next few years of earnings growth could mean for today’s valuation.

Read more »